Table 3. Summary of serum immunomodulatory proteins in women with endometriosis (EM+) and without (EM−).
| No. | Analyte | EM− Average Concentration (pg/mL) | EM+Mild Average Concentration (pg/mL) | EM+Sev Average Concentration (pg/mL) | % change EM+Mild to EM− | % change EM+Sev to EM− |
|---|---|---|---|---|---|---|
| 1 | IL-1β | 1.66 | 1.52 | 1.76 | 8.8 | −6.0 |
| 2 | IL-1rα | 128.29 | 118.58 | 138.18 | 7.6 | −7.7 |
| 3 | IL-4 | 3.51 | 3.33 | 3.90 | 5.3 | −11.0 |
| 4 | IL-6 | 7.54 | 8.12 | 10.87 | −7.7 | −44.2 |
| 5 | IL-7 | 14.70 | 11.60 | 15.13 | 21.1 | −2.9 |
| 6 | IL-8 | 14.60 | 12.28 | 14.10 | 15.8 | 3.4 |
| 7 | IL-9 | 15.79 | 8.51 | 16.36 | 46.1 | −3.6 |
| 8 | IL-10 | 12.60 | 7.63 | 9.94 | 39.5 | 21.1 |
| 9 | IL-12 (p70) | 28.66 | 11.74 | 23.33 | 59.0 | 18.6 |
| 10 | IL-13 | 7.12 | 1.61 | 4.47 | 77.4 | 37.2 |
| 11 | IL-17 | 17.17 | 2.15 | 9.08 | 87.5 | 47.2 |
| 12 | Eotaxin | 59.97 | 63.23 | 52.41 | −5.4 | 12.6 |
| 13 | FGF basic | 27.38 | 13.23 | 26.87 | 51.7 | 1.9 |
| 14 | G-CSF | 32.28 | 27.82 | 33.85 | 13.8 | −4.9 |
| 15 | IFN-γ | 144.70 | 131.87 | 158.86 | 8.9 | −9.8 |
| 16 | IP-10 | 1186.68 | 826.18 | 1101.85 | 30.4 | 7.1 |
| 17 | MCP-1 | 17.90 | 20.21 | 22.55 | −12.9 | −26.0 |
| 18 | PDGF-bb | 8491.17 | 5277.85 | 7611.71 | 37.8 | 10.4 |
| 19 | MIP-1β | 107.28 | 76.52 | 87.59 | 28.7 | 18.4 |
| 20 | TNF-α | 25.25 | 23.03 | 30.69 | 8.8 | −21.5 |
| 21 | VEGF | 104.87 | 25.43 | 96.96 | 75.7 | 7.5 |
EM−, women without endometriosis; EM+Mild, women with rAFS I or II endometriosis; EM + Sev, women with rAFS III or IV endometriosis.